HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
DESTINY-CRC01 (NCT03384940) was a multicentre, open-label, phase 2 study that investigated the safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing metastatic colorectal cancer (CRC). The present exploratory biomarker analysis aims to investigate relationships between biomarkers and clinical outcomes in patients with HER2-positive (immunohistochemistry [IHC] 3+ or IHC 2+ and in situ hybridization [ISH] positive) Cohort A (N = 53) of DESTINY-CRC01. Higher levels of HER2 biomarkers in baseline tissue and liquid biopsies, including HER2 status (IHC/ISH), HER2/CEP17 ratio, HER2 ISH signals, HER2 H-score, plasma HER2 (ERBB2) amplification status, HER2 adjusted plasma copy number, and HER2 extracellular domain correlate with antitumor activity (indicated by objective response rate, progression-free survival, and overall survival) of T-DXd. Baseline circulating tumor DNA (ctDNA) analysis suggests antitumor activity of T-DXd in patients who had baseline activating RAS, PIK3CA, or HER2 mutations detected in ctDNA. The phase 2 trial, DESTINYCRC01, previously demonstrated durable activity of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic colorectal cancer refractory to standard treatment. Here, the authors report the exploratory analysis of the DESTINY-CRC01 trial investigating markers of response or resistance to T-DXd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Clinical trials such as HERACLES [60], MyPathway [61], DESTINY-CRC01 [59], and MOUNTAINEER [62] have demonstrated significant clinical activity of HER2-targeted therapies in patients with HER2-positive, RAS-wild-type mCRC.”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“These are likely acquired mutations because all 6 patients had received anti-EGFR antibody therapy (4 cetuximab, 1 panitumumab, 1 cetuximab and panitumumab) prior to T-DXd treat-ment and acquired RAS mutations are a known resistance mechanism to EGFR inhibitors 28 .”
Self-citationCervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Self-citationOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016 · cited 1×
“Similar fi ndings were previously reported in the HERACLES-A trial of trastuzumab and lapatinib dual-targeted therapy, inwhichpatientswithahigher HER2 copynumberachievedlongerPFS and OS 24 , and patients with a higher HER2 ApCN achieved higher ORR and longer PFS 25 .”
Self-citationOgitani, Y., Hagihara, K., Oitate, M., Naito, H., & Agatsuma, T. (2016) · Cancer Science · doi:10.1111/cas.12966 · Cited by 751 · cited 2×
“The T-DXd bystander effect that kills adjacent tumor and stromal cells, has been described, with no potential overlapping mechanisms of resistance with the HER2 signaling pathway 19,31 .”
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Self-citationStrickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00150-x · Cited by 259 · cited 1×
“15 .”
Self-citation
Cited by
Cancer in a drop: Advances in liquid biopsy in 2024
Borea, R., Saldanha, E. F., Maheswaran, S., Nicolò, E., Singhal, S., Pontolillo, L., de Miguel‐Pérez, D., Venetis, K., Dipasquale, A., Ghazali, N., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104776 · Cited by 46
Holz, A., Paul, B., Zapf, A., Pantel, K., & Joosse, S. A. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102999 · Cited by 27
Hong, Y., Li, J., Xu, N., Shu, W., Chen, F., Mi, Y., Geng, H., & Li, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604154 · Cited by 17
Antibody–Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology
Jang, J. Y., Kim, D., Lee, N. K., Im, E., & Kim, N. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136523 · Cited by 24
Palieri, R., Luca, M. D., Balestra, F., Panzetta, G., Lotesoriere, C., Rizzi, F. R., Ricci, A. D., Mastrogiacomo, R., Curri, M. L., Laghi, L., et al. (2025) · Oncology Reviews · doi:10.3389/or.2025.1702932 · Cited by 17
Metadata
- Authors
- Siena, S., Raghav, K., Masuishi, T., Yamaguchi, K., Nishina, T., Elez, E., Rodriguez, J., Chau, I., Di Bartolomeo, M., Kawakami, H., Suto, F., Koga, M., Inaki, K., Kuwahara, Y., Takehara, I., Barrios, D., Kobayashi, K., Grothey, A., & Yoshino, T.
- Affiliations
- University of Milan (IT)
- The University of Texas MD Anderson Cancer Center (US)
- Aichi Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- Shikoku Cancer Center (JP)
- Royal Marsden NHS Foundation Trust (GB)
- Kindai University Hospital (JP)
- Daiichi Sankyo (United States) (US)
- Daiichi-Sankyo (Japan) (JP)
- West Cancer Center (US)
- National Cancer Center Hospital East (JP)
- Corresponding author
- Siena, Salvatore
- ORCID
- Venue
- Nature Communications
- Published
- 2024-11-25
- Volume
- 15
- Issue
- 1
- Pages
- 10213-10213
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC11589615
- OpenAlex
- W4404672172
- Cited by
- 30
- References
- 31
- Citations by year
- 2026: 15 · 2025: 15
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-01-15)
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Daiichi Sankyo
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- trastuzumab deruxtecan, HER2/CEP17 ratio, HER2 extracellular domain, circulating tumor DNA, RAS mutations, PIK3CA mutation, HER2 mutation, predictive biomarkers, treatment response, treatment resistance
- MeSH terms
- Trastuzumab, Circulating Tumor DNA, Antineoplastic Agents, Immunological, Progression-Free Survival, Adult, Aged, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Biomarkers, Tumor, Colorectal Neoplasms, Treatment Outcome, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. https://app.cochat.ai/papers/10.1038/s41467-024-53223-3
- The paper
- Siena, S., Raghav, K., Masuishi, T., Yamaguchi, K., Nishina, T., Elez, E., Rodriguez, J., Chau, I., Di Bartolomeo, M., Kawakami, H., Suto, F., Koga, M., Inaki, K., Kuwahara, Y., Takehara, I., Barrios, D., Kobayashi, K., Grothey, A., & Yoshino, T. (2024). HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nature Communications. https://doi.org/10.1038/s41467-024-53223-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.